Clinical trials have investigated the weight loss effect of glucagon‐like peptide‐1 receptor
agonists (GLP‐1 RA) in adults with obesity without diabetes mellitus, but results for weight …

Aims To determine the effects of glucagon-like peptide-1 receptor agonists compared with
placebo and other anti-diabetic agents on weight loss in overweight or obese patients with …

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are new drugs for the
treatment of obesity. Objective To assess the weight-loss effects of GLP-1RAs in the …

Background Comparative effectiveness of 7 glucagon-like peptide 1 (GLP-1) agents on
weight loss (WL) in obesity remains unknown. Methods We performed a systematic review …

Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor
agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in …

Glucagon‐Like Peptide‐1 receptor agonists (GLP‐1RAs), approved as glucose‐lowering
drugs for the treatment of type 2 diabetes, have also been shown to reduce body weight. An …

Purpose Published data on the weight loss effects of glucagon-like peptide 1 (GLP-1)
receptor agonists are reviewed, with a focus on data from clinical trials. Summary Obesity is …

Objective Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), initially for type 2
diabetes mellitus, show promise in promoting weight loss and improving heart health in …

To evaluate the effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) on
weight reduction in patients with Type 2 diabetes mellitus (Type 2 DM), a network meta …

Objective To determine whether treatment with agonists of glucagon-like peptide-1 receptor
(GLP-1R) result in weight loss in overweight or obese patients with or without type 2 …